Floatz logo

Raltitrexed

Regorafenib

China Medical University, ChinaSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Regorafenib cohort.

Asset / SponsorPhaseRating
Regorafenib
M.D. Anderson Cancer Center
Phase 3BB
Irinotecan
Sun Yat-sen University
Phase 3B
Lorigerlimab
M.D. Anderson Cancer Center
Phase 2CCC
Tuvonralimab
JIANG LONGWEI
Early Phase 1C
Iparomlimab
JIANG LONGWEI
Early Phase 1C

View all 9 →

Same molecule, other indications

Raltitrexed is also rated in:

Hepatic Arterial Infusion ChemotherapyDormant
BBB
Indicative ·
74 / 100
View asset →
Colon Cancer Liver MetastasisDormant
BB
Indicative ·
71 / 100
View asset →
Hepatocellular CarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →